期刊
HEALTHCARE
卷 10, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/healthcare10010038
关键词
secondary immune thrombocytopenia; autoimmune disease; malignancy; infection; clinical practice guideline
In Malaysia, there have been limited studies on secondary immune thrombocytopenia (sITP), with most research focused on primary ITP. However, existing studies suggest that sITP in Malaysia is commonly associated with autoimmune diseases, malignancy, and infections. More research is needed to understand the mechanisms behind these associations and to update the existing guidelines for ITP management in Malaysia.
Immune thrombocytopenia (ITP) is an acquired autoimmune disease that occurs in adults and children. In Malaysia, the clinical practice guideline (CPG) for the management of ITP was issued in 2006, which focused almost exclusively on primary ITP (pITP), and only a few secondary ITP (sITP) forms were addressed. All published (twenty-three) sITP articles among children and adults in Malaysia, identified on the academic databases were retrieved. The articles were published between 1981 and 2019, at a rate of 0.62 publications per year. The publications were considered low and mainly focused on rare presentation and followed-up of secondary diseases. This review revealed that sITP in Malaysia is commonly associated with autoimmune diseases (Evan's syndrome, SLE and WAS), malignancy (Kaposi's sarcoma and breast cancer) and infection (dengue haemorrhagic fever, Helicobacter pylori and hepatitis C virus). The relationship between ITP and autoimmune diseases, malignancy and infections raise the question concerning the mechanism involved in these associations. Further studies should be conducted to bridge the current knowledge gap, and the further information is required to update the existing CPG of management of ITP in Malaysia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据